posted
Superman 7- Welcome. Looking at level 2 I would say .003 is the line MM's have drawn in the sand so look for a little pull back here and then hopefully we'll be back up to try to hack through some of these asks (8 at .003). I got in at .00245 and haven't seen anything close to the volume we are seeing today (22 day average volume is 7million) so I don't really know what to expect today. Good Luck
posted
Boy with this much volume I just don't know what to expect!!! Man look at her go! L2 looks like another fre wall set up at .0035 but heck I thought that at .003 too! Just when I'm starting to think I know something...
posted
Jim - I agree with multi day run scenario but I think we need news early next week and need to close .03 or higher with EOD run close to high of day!!!
posted
Yes a close at .03!! I love it. What are you thinking for next week Jim? I'm thinking with news this will skyrocket. Your 400% in 4 weeks prediction is looking dead on right now. Volume was huge today and the good news is we spent all day chewing through millions of shares in the .03 range. Should soften that level up for next week!!! Do you think we need news for this to run or are you convinced we'll run regardless?
posted
I flipped this puppy once before from .02 to .04.
I flipped again on Friday from .023 to .032. I'll take the 30%-ish gain and put it in my pocket.
I am really liking this stock, I think it is one of the few pennies you can feel secure putting your money in and letting it sit overnight. I totally like where this comany seems to be heading. I'll watch Mondays action and jump back in with my initial investment and get ready to flip again.
posted
DJ- What do you expect on Monday? DNAG moves pretty solidly with news too. I think without news we will see a slight dip to just below .03. Then when news hits this puppy will fly straight to at least .035.
posted
Does any one have insight on Friday's press release? 35million dollar Financing agreement. I am concerned about this but don't know much about the financing end of things.
TEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On March 13, 2006, the Registrant issued to Dutchess Private Equities Fund, L.P. ("Dutchess") a promissory note (the "Note") in the amount of $1,500,000 for a purchase price of $1,200,000.
As previously reported, on September 28, 2004, the Registrant entered into an Investment Agreement (the "Investment Agreement") with an affiliate of Dutchess, pursuant to which Dutchess has committed to purchase common stock of the Registrant up to an aggregate purchase price of $35 million over a two year period. The Dutchess Agreement provides that the Registrant from time to time may deliver a put notice to Dutchess, and Dutchess is obliged to purchase the dollar amount of common stock set forth in the notice.
The Note is due and payable in full on March 6, 2007. Other than the discount inherent in its purchase price, the Note is noninterest-bearing. The Note will be repaid using 100% of the proceeds of each put notice delivered by the Registrant to Dutchess under the Investment Agreement. The Note is also secured by a security interest in substantially all of the Registrant's assets pursuant to a Security Agreement dated October 21, 2005 with Dutchess.
In connection with the Note, the Registrant also paid Dutchess a facility fee of $65,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $330,000 payable on March 6, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess's option at a conversion price equal to $0.01 per share.
IP: Logged |
posted
No wait I'm confused here as usual... Dutchess will purchase $35M worth of common stock AND get CD's? So they purchase stock and then also convert CD's? Purchasing stock will raise the PPS thus letting them convert less shares? Why would they do both or would they convert first and than purchase?
posted
OLMP is the story again today, selling into the run and volume has slowed tremendously. I have a hunch we will see some news tomorrow so should know for sure iif we see late day buying pick up.
posted
OLMP wins today. Constant dumping at .03 throughout today. Every buy today has been over .03 while the selling has been at .03 all day, killing every run. Too bad because Level 2 has looked ripe for a run to .035 all day.
posted
Well the MM's seemed to have gotten their shake today.
I hope to get back in at .026 tomorrow after selling at .032 last week. I think we will see .032 then .035 before long. And we know DNAG likes their press releases and volume has still been pretty darn strong.
IP: Logged |
posted
Updated:2006-04-13 07:25:53 DNAPrint Genomics Ancestry Technology Highlighted in Article in the New York Times Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 04/13/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company's technology was highlighted in an article entitled "Seeking Ancestry in DNA Ties Uncovered by Tests" in the April 12, 2006 edition of The New York Times.
The article reported that genetic tests, once obscure tools for scientists, have begun to influence everyday lives in many ways and that people are utilizing them when applying for jobs and college scholarships. "The tests are reshaping people's sense of themselves -- where they come from, why they behave as they do, what disease might be coming their way," The Times reported.
Commenting on the article following its publication, DNAPrint President and Chief Executive Officer Richard Gabriel said that there is a growing interest and demand for the Company's ANCESTRYbyDNA(TM) technology for determining family heritage. "In many instances, people who take the test want to determine whether they have American Indian or other ancestry to validate eligibility for college admission or scholarship programs. DNAPrint Genomics maintains the largest Native American DNA Database in North America."
In addition to its ANCESTRYbyDNA(TM) test for determining family heritage, DNAPrint Genomics' technology has forensic applications. The Company's DNAWITNESS(TM) product analyzes DNA taken from crime scenes, and has been utilized in more than 100 criminal investigations worldwide. DNAWITNESS(TM) test results have assisted investigators in many high profile criminal cases, including the apprehension and conviction of a serial killer in Louisiana.
posted
DNAPrint Genomics Receives Notice of Allowance for Patent for Identifying Links Between Gene Sequences and Medical Traits Sophisticated Technology Utilized by Company's DNAPrint Pharmaceuticals Subsidiary
SARASOTA, FL -- (MARKET WIRE) -- 04/20/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company has received a Notice of Allowance from the U.S. Patent and Tradmark Office for a patent application, Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits).
"Gene sequences are highly polymorphic in the population, which means that they come in various forms or 'flavors,'" stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Polymorphism is usually measured at the level of the single nucleotide polymorphism (SNP) but our technology measures at the level of the haplotype (strings of SNPs), which provides researchers considerably more information. The methods covered in the patent allow for an efficient and powerful means for identifying haplotype."
The recent patent provides legal protection for DNAPrint's status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual's predisposition to respond to certain drugs.
"The Company is committed to developing a new class of drugs, called 'theranostics,' which are test+drug combinations designed to help ensure that patients receive the appropriate medicine and proper dosage based on their genetic constitution. The application of theranostics is also designed to increase efficacy and reduce side-effects," said DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "Our sophisticated genetics technology is playing a key role in the research and development of potential new drugs."
Highlighted Links MacReport.Net DNAPrint™ genomics, Inc.
"This patent cuts across a wide audience of developers from drug companies to people working on technology in the forensics and consumer areas," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We plan to vigorously utilize and practice our patents and we will be reviewing the fields of genetic testing, drug development, forensic sciences and consumer products with our patent counsel to determine potential areas of development. We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."
DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
-------------------- w i k i s t o c k . c o m
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
